Survey reveals important differences in how
patients and physicians define disease remission and the importance
of remission as a clinical goal1
The high prevalence of corticosteroid
therapy currently in use in IBD management reflects a significant
unmet need for better therapies2
Findings suggest greater need for alignment
between patients and physicians on treatment goals and measures of
success as well as new treatment options that provide sustained
disease control beyond what is achieved with current
therapies1,2
Bristol-Myers Squibb Company (NYSE:BMY) today announced the
results of a robust multinational inflammatory bowel disease (IBD)
survey conducted among patients and physicians, with findings
revealing urgent and unmet needs in several key areas, including
differences in expectations between patients and physicians that
may impact disease management and treatment decisions.1,2 The IBD
Global Assessment of Patient and Physician Unmet Needs Survey (IBD
GAPPS) captured insights and perspectives from more than 2,000
patients and 600 physicians, exploring the physician-patient
relationship, how patients and physicians define remission, their
treatment expectations and levels of satisfaction with current
therapies, as well as the impact of ulcerative colitis (UC) and
Crohn’s disease (CD) on disease-related quality of life.1,2 Results
from the survey were presented at the 15th Congress of the European
Crohn's and Colitis Organisation (ECCO) in Vienna, Austria.
“As gastroenterologists and patients work together to best
manage IBD, we need to shift the conversation from focusing on
short-term goals like symptom relief to an emphasis on achieving
long-term disease control so that patients can lead productive
lives,” said David T. Rubin, M.D., Section Chief of
Gastroenterology, Hepatology and Nutrition, Co-Director, Digestive
Diseases Center, University of Chicago Medicine and Chair of the
IBD GAPPS Steering Committee. “IBD GAPPS provides real-world
insight into fundamental gaps in understanding, communication and
expectations between patients and physicians that are important to
consider in our approach to setting treatment goals and improving
long-term disease outcomes.”
IBD GAPPS, an Institutional Review Board (IRB)-approved survey,
was developed based on insights from a multinational steering
committee, input from patient and professional advocacy groups and
patient feedback.1 The online survey was conducted from August to
November 2019 in the United States, Canada, France, Germany, Italy,
Spain and the United Kingdom.1 It involved 2,398 patients aged 18
years or older diagnosed with ulcerative colitis or Crohn’s disease
who had taken prescription medication for their condition.1
Additionally, surveys were completed by 654 gastroenterologists
responsible for their patients’ treatment decisions who had an
average monthly caseload of 268 patients, including approximately
43 ulcerative colitis and 43 Crohn’s disease patients.1
“The IBD GAPPS findings illuminate emerging and underrecognized
needs that exist for patients and physicians,” said Michael Osso,
President and CEO, Crohn's & Colitis Foundation. “Our hope is
that these results create dialogue and urgency within the IBD
community to advance solutions that lead to better communication
between patients and providers, improved long-term disease control
and the best possible care for patients.”
Important Differences Exist Between How
Patients and Physicians Define Remission1
The survey revealed important and meaningful differences in how
patients and physicians define IBD remission.1 The majority of
physicians defined remission based on clinical test results (64
percent of physicians for CD, 70 percent for UC) whereas patients
(45 percent) most commonly defined remission as the resolution of
IBD symptoms.1 Additionally, while most physicians and patients
acknowledge discussing remission (93 percent of physicians, 78
percent of patients), their distinct definitions of remission
highlight a need for greater alignment.1
High Prevalence of Corticosteroid Use
Reflects Significant Unmet Need for Improved
Therapies2
Results from IBD GAPPS showed that more than one-third of IBD
patients (35 percent of CD patients, 39 percent of UC patients)
used corticosteroids for four or more months over the past year to
control their disease.2 Physicians believe more than 40 percent of
IBD patients will require four or more months of corticosteroid use
per year to maintain disease control.2 Yet despite high patient
concern over any corticosteroid use, and most patients wanting to
stop corticosteroid treatment as soon as their disease is under
control, only approximately 50 percent of physicians expressed
concern over four or more months of corticosteroid use per
year.2
Physicians’ Satisfaction with Remission
Rates & Sustained Treatment Response May Impact Treatment
Outcomes1
Based on the survey findings, physicians’ satisfaction with
relatively low IBD remission and durability rates may suggest an
acceptance of sub-optimal outcomes in chronic disease control.1
Physicians indicated up to 63 percent of IBD patients will not
obtain remission with current therapies; however, many physicians
are highly satisfied with these results (25 percent of physicians
for CD, 36 percent for UC).1 Additionally, physicians (up to 58
percent for UC and up to 63 percent for CD) reported that they see
an average sustained response of at least one or at least two years
with current therapies, with most physicians moderately to highly
satisfied with these results.1
Despite these low physician expectations, most patients believe
remission is a feasible treatment goal, and approximately one-third
of patients expect their treatment to provide five or more years of
disease control.1 These expectations exist despite many patients
(61 percent) reporting only partial IBD control with current
therapies.1
“The IBD GAPPS data presented at ECCO underscore BMS’s
commitment to partnering with the IBD community to highlight urgent
and significant unmet needs impacting care for patients,” said Mary
Beth Harler, M.D., Head of Immunology and Fibrosis Development,
Bristol-Myers Squibb. “We recognize the debilitating impact that
ulcerative colitis and Crohn’s disease can have on the lives of
patients, and together with the community, are focused on solutions
that transform outcomes for all those impacted by these
diseases.”
Bristol-Myers Squibb plans to submit the survey findings for
publication in a peer-reviewed journal and present additional
findings at future scientific congresses.
About IBD GAPPS1
The IBD Global Assessment of Patient and Physician Unmet Needs
Survey (IBD GAPPS) evaluated how moderate to severe ulcerative
colitis (UC) and moderate to severe Crohn’s disease (CD) impacted
the lives of patients.1 IBD GAPPS, which was approved by an
Institutional Review Board (IRB), was developed based on insights
from a multinational gastroenterologist steering committee, input
from patient and professional advocacy groups and patient feedback.
This internet-based survey was conducted across the United States,
Canada, France, Germany, Italy, Spain and the United Kingdom.1 It
involved 2,398 patients aged 18 years or older who had taken a
prescription medication for their disease. Of the patients taking
the survey, 78 percent of UC patients and 93 percent of CD patients
had moderate to severe disease.1 Additionally, surveys were
completed by 654 gastroenterologists responsible for their
patients’ treatment decisions who had an average monthly caseload
of 268 patients, including approximately 43 ulcerative colitis and
43 Crohn’s disease patients.1 Approximately 62 percent and 67
percent of their UC and CD patients, respectively, were classified
as moderate to severe.1
About Bristol-Myers
Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol-Myers Squibb, visit us at BMS.com or
follow us on LinkedIn, Twitter, YouTube, Facebook and
Instagram.
Celgene and Juno Therapeutics are wholly owned subsidiaries of
Bristol-Myers Squibb Company. In certain countries outside the
U.S., due to local laws, Celgene and Juno Therapeutics are referred
to as, Celgene, a Bristol-Myers Squibb company and Juno
Therapeutics, a Bristol-Myers Squibb company.
References
- Afzali A, et al. Patient and physician perspectives on the
management of Inflammatory Bowel Disease: Disease remission and
durability of treatment. Poster 482. Presented at 15th Congress of
ECCO 2020.
- Afzali A, et al. Patient and physician perspectives on the
management of Inflammatory Bowel Disease: Role of steroids in the
context of biologic therapy. Poster 393. Presented at 15th Congress
of ECCO 2020.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200214005055/en/
Bristol-Myers Squibb Company Media Inquiries:
609-252-3345 media@bms.com Investors: Tim Power 609-252-7509
Timothy.Power@bms.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024